Introduction
Lacosamide was approved as an adjunct therapy for the treatment of partial-onset seizures by the European Commission in September 2008 and by the US FDA in October 2008. Here we present a patient with simple motor status epilepticus that was successfully aborted with the addition of lacosamide to levetiracetam when three other AEDs failed.
Case description
A 57-year-old man from Eritrea with cognitive and language impairment from traumatic brain injury suffered at age 25 presented with right arm and leg weakness. Because of his baseline communication difficulties, his family provided the history. They described a two-day history of repeatedly dropping objects held in his right hand and accompanying falls. The right arm and right leg weakness was static and accompanied by involuntary jerking movements. His remote history of traumatic brain injury was followed 7 years later by the onset of epilepsy that had been treated with phenytoin monotherapy without known seizure recurrence. On examination, he was oriented only to himself and not to date or place. Speech was non-fluent with frequent perseveration of the word ''exceptionally.'' Cooperation existed for only simple commands. A mild pronator drift of the right arm was present and right upper extremity grip was slightly weaker than left. Tone within the right hand was mildly increased. When at rest, a low-amplitude 1 Hz rhythmic thumb contraction was present. EEG revealed persistent left posterior slowing and frequent left occipital epileptiform rhythms that often spread to include the centroparietal region (Fig. 1) . MRI demonstrated cystic encephalomalacia of the left parietal, occipital, and posterior temporal lobes with an area of DWI/FLAIR hyperintensity consistent with ongoing focal seizures (Fig. 2) .
In the emergency room, 2 mg of IV lorazepam was administered. Phenytoin serum concentration on admission was 4 mcg/ml and the patient was loaded with 1000 mg of intravenous fosphenytoin followed by 3000 mg of intravenous levetiracetam. Maintenance doses of phenytoin 360 mg daily and levetiracetam 1500 mg twice daily were then started. Laboratory studies including hematologic and chemistry panels with calcium, magnesium, and liver enzymes were normal. Continuous EEG monitoring was started 4 h after his initial presentation, which demonstrated that his seizures briefly subsided with residual persistent left posterior slowing and frequent epileptiform discharges over the left posterior region. However, frequent electrographic seizures returned on the subsequent day with durations of 50-60 s and localization restricted to the left posterior region despite administering another 2 mg of lorazepam intravenously. The epileptic movements of the right hand occurred with Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam failure. We report a case of simple motor status epilepticus refractory to benzodiazepines and multiple anti-epileptic medications (AEDs) over 4 days. The addition of lacosamide in combination with existing levetiracetam aborted the continuous seizure with maintenance of seizure freedom through the most recent follow-up at 4 weeks.
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less the 10% of these EEG events; however, there was persistent right hand dysfunction. Intravenous valproate was loaded at a dose of 20 mg/kg and maintained at 10 mg/kg every 6 h. This was continued for 33 h but was not effective in controlling the seizures. The levetiracetam dose was then increased to 2000 mg twice daily and the phenytoin dose was increased to achieve a serum concentration in the range of 20-30 mcg/ml. Despite these changes, electrographic seizures continued to occur four to eight times an hour and behavioral seizures occurred one to two times every 2 h. Several seizures occurred during meals, at which time the patient was noted to be unable to feed himself using his right hand. After 4 days of refractory focal motor status epilepticus with EEG monitoring, oral lacosamide tablet was started at 50 mg twice daily given the refractory nature of the seizures to standard treatment. The oral formulation was chosen because it provided sufficiently fast introduction of the medication; though in retrospect, IV formulation should have been considered given the desire to stop the seizures as soon as possible. ECG prior to initiation of lacosamide was normal. Phenytoin was tapered to discontinuation by 100 mg per day every two days to minimize side effects from polytherapy. Valproate was tapered to discontinuation by 500 mg/day every 2 days because of drowsiness and a rising serum ammonia concentration. With levetiracetam continued use, the electrographic seizures stopped on the forth day after lacosamide was started. The right hand function improved and no other potentially confounding provoking factors were found. After five days on lacosamide 50 mg twice a day, the dosage was titrated up 100 mg twice a day for 3 days, then to 200 mg twice a day. The patient remained seizure free for 5 days on EEG monitoring before he was discharged home on levetiracetam 2000 mg twice daily and lacosamide 200 mg twice daily without any side effects such as drowsiness or dizziness.
One month later, the patient returned for outpatient care. There had been no seizure recurrence. A repeat EEG showed moderate left hemispheric slowing without epileptiform discharges.
Discussion
Lacosamide is approved as an adjunctive therapy for the treatment of partial-onset seizures. Since its introduction, there has been one reported case of successful use in the treatment of non-convulsive status epilepticus 1 and one reported case of successful treatment of convulsive status epilepticus 2 in the English literature. There is also a case of successful treatment with lacosamide in partial status epilepticus in Spanish. 3 As is commonly observed and previously described, seizure control becomes progressively more difficult to achieve with time, 4 and we observed this difficulty with our patient who had refractory seizures over 4 days despite a combination of phenytoin, valproate, and levetiracetam. Our eventual successful treatment with lacosamide further supports the potential of this medication to treat refractory status epilepticus. While seizure resolution independent of lacosamide's use for this patient remains a possibility, a benefit from lacosamide is likely because seizure resolution occurred within 24 h of the first lacosamide dose while other AEDs were tapered off quickly.
[ ( ) T D $ F I G ] This is one of the first reported cases of successful treatment of refractory simple motor SE with the addition of lacosamide. The benefit we observed may have been due to lacosamide or due to a combination of lacosamide with levetiracetam. Given that lacosamide has a different mechanism of action from other AEDs, including its ability to enhance the slow inactivation of voltagegated sodium channels, 5 combination therapy should be explored.
We also demonstrated that rapid oral lacosamide titration reaching 400 mg total daily in 8 days can be used in urgent situations without significant side effects. Recently published 6 , Kellinghaus et al. reported a larger series of patients treated with IV lacosamide at the 2009 American Epilepsy Society meeting, and ultimately, more case series or a controlled trial would be necessary to further elucidate lacosamide's benefit in simple motor SE.
